EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Pages:

15

TR-1 notification of major interest in shares

21^st Mar 2016

TR-1 notification of major interest in shares

21^st Mar 2016

TR-1 notification of major interest in shares

21^st Mar 2016

Second Price Monitoring Extension

17^th Mar 2016

Price Monitoring Extension

17^th Mar 2016

Notice of Results

17^th Mar 2016

EKF Diagnostics Holdings plc announces Notice of Results.

3^rd Feb 2016

EKF Diagnostics Holdings plc announces a trading update for the year ended 31 December 2015.

TR-1 notification of major interest in shares

20^th Jan 2016

TR-1 notification of major interest in shares

18^th Jan 2016

Price Monitoring Extension

18^th Jan 2016

Pages:

15

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

New study reaffirms Quo-Test A1c meets IFCC performance criteria

EKF Diagnostics, the global in vitro diagnostics company, announces that in a newly published paper its Quo-Test^® point-of-care (POC) hemoglobin A1c (HbA1c) analyzer has again been confirmed to meet International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) performance criteria.

New Procalcitonin (PCT) study shows that testing reduces hospital costs and length of stay

A recent study published in CHEST found that the use of PCT screening on the first day of ICU admission was linked to significantly shorter hospital stays, as well as an overall decrease in cost of care.

EKF Diagnostics announces the launch of its new USA domestic website www.ekfusa.com

EKF Diagnostics announces the launch of its new USA domestic website www.ekfusa.com.

EKF Diagnostics is previewing the new connectivity solution for A1c POC analyzers at Medica 2016

EKF Diagnostics is previewing a new point-of-care (POC) connectivity solution for its range of HbA1c analyzers at Medica 2016 in Düsseldorf from 14–17^th November.

Glycated Serum Protein LiquiColor test verified for Siemens Vista chemistry analyzer

EKF Diagnostics, the global in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor^® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer

Product showcase

Copyright © 2020 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

ekf orange

Please note: Not all products are available in all countries. Please check availability.

Privacy | Terms & Conditions | Terms of Sale | UK Modern Slavery Act